MYL9

Across TCGA pan-cancer cohorts, MYL9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYL9 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MYL9 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MYL9 expression acts as an unfavorable survival marker.

CCRCC, PDAC, and LSCC are the cancer types where MYL9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	IV	0.198	0.830	.024	12	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	9	view →
LSCC	OS	Tertile	All	0.612	1.000	.019	4	view →
GBM	DFS	Quartile	All	0.249	0.495	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MYL9–CCRCC (OS)

Open the CCRCC breakdown →